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Introduction
Adenocarcinomas of the small bowel (SBA) are ra-
re cancers comprising 0.1 to 0.3% of all malignancies
(1). Recent data suggest that the annual incidence of
SBA is in the range of 2.2-5.7/million population/year
in the Western countries (2). This paucity of cases has
resulted in few systematic researches on the pathogene-
sis, natural history and treatment of SBA (1, 2).
Despite the fact that the small intestine has the lar-
gest mucosal surface area in the gastrointestinal (GI) tract
(more than 90%), it is the site of only 2% of all primary
GI tumors. SBAs represent approximately 25% of all
small bowel neoplasms (benign and malignant) and 30-
50% of all malignant tumors of small bowel. The SBA
incidence is only one-fortieth to one-fiftieth in compa-
rison with the incidence of the adenocarcinoma of the
large intestine (3). 
The small bowel appears to be relatively resistant to
the development of tumors. A variety of factors have
been proposed to explain the rare occurrence of SBA,
such as the rapid small bowel transit, the large volume
of secretions reducing the intraluminal concentration of
carcinogens, the low level of bacteria compared to the
colon minimizing the formation of procarcinogens from
the degradation of bile salts, the high turnover of small
bowel mucosal cells inhibiting competitively the growth
of malignant cells, finally the high level of IgA (4, 5). 
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Small bowel adenocarcinoma is a rare tumor, with a still not well
studied tumorigenesis process, usually presenting in an advanced stage.
The clinical diagnosis is often difficult; surgery is the treatment of choi-
ce when feasible, while the chemotherapic approach is still not well co-
dified. 
We describe the case of a 71-yr-old male patient, presenting with
an acute right abdomen. At laparotomy the terminal ileum appeared
chronically inflamed and thickened. An ileocecal resection with latero-
lateral ileocolic anastomosis was performed. The gross appearance resem-
bled an inflammatory bowel disease, but microscopic examination re-
vealed the extensive presence of an infiltrating ileal adenocarcinoma.
Literature about small bowel adenocarcinoma has been reviewed
for better understanding its pathogenesis. 
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L’adenocarcinoma dell’intestino tenue è un tumore raro, con un pro-
cesso di tumorigenesi non ancora ben studiato e che di solito si presen-
ta in uno stadio avanzato. La diagnosi clinica è di regola difficile; la
chirurgia è il trattamento di scelta, quando possibile, mentre l'approccio
chemioterapico non è ancora ben codificato. 
Descriviamo il caso di un paziente di 71 anni giunto alla nostra os-
servazione con quadro di addome acuto destro. Alla laparotomia, l’ileo
terminale era infiammato ed ispessito. Si eseguiva una resezione ileo-cie-
cale, con anastomosi ileocolica latero-laterale. L’aspetto macroscopico era
quello di una malattia infiammatoria intestinale, ma l'esame microsco-
pico rivelava la presenza estesa di un adenocarcinoma infiltrante ileale.
Si è proceduto ad un’analisi della letteratura sull’adenocarcinoma del
piccolo intestino, con l'intento di comprenderne meglio la patogenesi.
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The four major types of primary small bowel mali-
gnancies are adenocarcinoma, sarcoma, carcinoid tu-
mors, and lymphomas, of which the most prevalent is
adenocarcinoma (6). The peak incidence of SBA is re-
ported to occur in the 6th and 7th decades (7). The mo-
st common onset symptoms are abdominal pain, ga-
strointestinal bleeding and weight loss. The obstruction
is frequent and it is typically intermittent. The average
duration of symptoms before diagnosis is between 6 and
12 months. Most intestinal carcinomas are infiltrative
tumors and have a high tendency to circumferential
spread through the intestinal wall. Tumor size at surgery
ranges from 1-9 cm with a mean of 4.5 cm (7). Long
stenosis is uncommon. Milman and Gallego described
two cases of “long” SBA (respectively 10 and 20 cm) in-
volving the terminal ileum, simulating Crohn’s disease,
with irregular narrowing and thickening of the wall (8,
9). Less frequently, the tumor grows into the lumen as
a polypoid lesion (8). Polypoid adenocarcinomas may
present with intussusception (7). Early adenocarcinomas
in the small intestine are a rare entity. Only 3-10% of
SBA are found in stage T1 and 0-3% in stage Tis (10).
The lack of specific symptoms and rarity of SBA con-
tribute to advanced-stage presentation (11). Among pa-
tients staged according to the American Joint Commit-
tee on Cancer (AJCC) schema, 2.7% were stage 0, 12%
stage I, 27% stage II, 26% stage III, and 32.3% stage
IV (12). Howe et al. observed that patients with poorly
differentiated tumors had a significantly decreased 5-year
disease specific survival (DSS) (22.4%) compared with
that for patients with well-differentiated tumors (39.4%)
and moderately differentiated to well-differentiated tu-
mors (33.3%) (13). Tumor stage is also significantly cor-
related with survival. In the AJCC stage groups, the DSS
rate for patients with stage IV disease (4.2% 5-year DSS)
was significantly worse than for patients with stage I-
III disease (65.1% 5-year DSS for stage I disease, and
35.4% 5-year DSS for stage III disease) (13).
SAB are aggressive with poor 5-yr overall survival of
around 20-30% in various studies. The survival is di-
rectly related to the potential for surgical resection with
intent to cure (6). Because of the small number of pu-
blished cases and the lack of appropriated randomized
prospective studies, the optimal therapeutic strategy has
not been exactly defined as yet (4). For localized disea-
se, surgical resection is the mainstay of therapy becau-
se complete removal of tumor and of draining lymph
nodes is one of the most important predictors of survi-
val. The 5-year survival rate ranges from 40-60% in re-
sected to 15-30% in non-resected patients. Limited
small resection may also be indicated in metastatic di-
sease to relieve local symptoms such as obstruction and
tumor bleeding (4). Regarding adjuvant chemotherapy,
neither the indication nor the optimal regimen has yet
been exactly defined. Adjuvant chemotherapy is usual-
ly recommended in locally advanced tumors or in tho-
se with lymphatic spread. Because no advantage of adju-
vant therapy for stage II disease in SBA has been demon-
strated, Eigenbrod et al. do not see an indication for
adjuvant treatment after resection of the primary tumor.
They describe advantages only in patients with stage IV
disease (4). Currently, chemotherapy regimens for SBA
are extrapolated primarily from the experience with co-
lorectal cancer or upper GI tract cancers, but this is
clearly a suboptimal approach. 
The increased understanding of the pathogenesis and
tumorigenesis of SBA may provide potential candida-
tes for therapeutic targets. A number of studies have re-
ported biological markers implicated in SBA tumorige-
nesis, orienting to the development of molecular agents
targeting critical pathways (2).
Case report
A 71-yr-old male patient was admitted to our Department for
acute abdomen, with severe pain in the right iliac fossa. The patient
was in good general status, and his medical history was unremarka-
ble for significant pathologies, past malignancies, familiarity for in-
testinal tumors, environmental risk factors. Abdominal X-ray shows
intestinal obstruction. 
At surgery the terminal 20 cm of ileum appeared chronically in-
flamed and thickened. An ileocecal resection, involving 60 cm of
bowel, with latero-lateral ileocolic anastomosis was performed. 
The gross appearance resembled an inflammatory bowel disea-
se (IBD) for the presence of various-sized, irregular mucosal ulcers,
several elevated sessile nodules and fibrotic consistence of a 20 cm
bowel wall. Microscopic examination of routine sections revealed the
extensive presence of an infiltrating Not Otherwise Specified (NOS)
adenocarcinoma. This lesion measured 20 cm in his greatest dimen-
sion; it was a moderately differentiated adenocarcinoma, infiltran-
ting muscular layer, without regional lymph nodes metastasis. On
the immunohistochemical study, the tumor expressed CEA (Fig. 1)
and cytokeratin 20 (CK20), but it was negative for Cdx2 (Caudal-
related homebox2) and p53 oncoprotein. 
EGFR (Epidermal Growth Factor Receptor) immunostaining
reaction has been tested and revealed a focal and incomplete posi-
tivity (Fig. 2). The postoperative period was uneventful and the pa-
tient was discharged 7 days after the surgery. After eleven months
the patient is alive without evidence of disease, undergoing regular
oncological follow-up.
Discussion
The majority of SBA are histologically moderately
to poorly-differentiated (14), and are found, in decrea-
sing order of frequency, in the duodenum (47-55%),
jejunum (18-29%), ileum (14-24%), and 14% in not
specified sites (3,10). Duodenal adenocarcinomas
usually arise in the periampullary region, suggesting that
biliary secretion might play a role in tumor development.
The ileum is an uncommon location for adenocarcino-
mas (3). 
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Interesting observation is the very high rate of second
malignancies in SBA patients. In a recent population-
based study consisting of 10, 946 cases from 13 cancer
registries, there was a 68% increase in the risk of a se-
cond primary cancer after SB carcinoma (15). The on-
set of SBA may signify a particularly unstable genomic
situation, and may lead to a strong predisposition to ad-
ditional malignancies (2).
Risk factors for SBA include hereditary gastrointe-
stinal cancer syndromes (such as familial adenomatous
polyposis, hereditary non-polyposis colorectal cancer
syndrome or HNPCC and Peutz-Jeghers syndrome), in-
flammatory bowel disease (in particular Crohn’s disea-
se), cystic fibrosis, celiac disease, ileostomy, ileoanal pou-
ch anastomosis (IPAA), cystoplasty, radiation therapy,
and congenital bowel duplications (3, 16-21). Murphy
et al. described an unusual case of Turcot’s syndrome as-
sociated with ileal adenocarcinoma, intestinal non-
Hodgkin’s lymphoma, and duodenal adenocarcinoma
(22). Neurofibromatosis and SBA association has also
been described (23-25).
Further data suggest that SBA originate via an ade-
noma-carcinoma sequence, as described for colon can-
cer, with mutations in key growth regulating genes. Se-
veral epidemiological and pathological similarities ha-
ve been identified between colorectal adenocarcinomas
and SBA, leading to the hypothesis that some genetic
mechanisms responsible for colorectal cancer (CRC) mi-
ght also be involved in the development of SBA (3, 5).
In a recent study, Onuma et al. reported a frequent phe-
notypic transformation from small intestinal epithelium
into colonocytes in small intestinal adenomas and ade-
nocacinomas (26). 
In 2005 Delaunoit et al. reviewed pathogenesis and
risk factors of SBA, with the purpose of better under-
standing its molecular features and its similarities with
CRC (3). Both tumor types usually arise from pre-exi-
sting adenomas, with an estimated one-third of solitary
small bowel adenomas trasforming into invasive carci-
nomas. SBA, as well as CRC, are most frequent in pa-
tients with a history of chronic inflammatory bowel di-
sease and in patients with hereditary gastrointestinal can-
cer (3). Ki-ras is most frequently mutated on codon 12
in CRC, and is usually an early event in tumorigenesis.
Available data show that Ki-ras mutations are observed
in 14-83% of SBA cases, and particularly in duodenal
locations (3). Codon 12 Ki-ras mutation is also found
in 40-50% of small bowel adenomas, which is similar
to that observed in large bowel locations (27). Rashid
et al. demonstrated complete concordance in Ki-ras mu-
tation between tissues from adenocarcinomas and con-
tiguous adenomas in their cases, suggesting a relation-
ship between the demonstrated adenoma-carcinoma se-
quence and Ki-ras mutation in SBA (28). 
In CRC p53 mutation seems to be a rather late event
in adenoma-carcinoma sequence. Similarly, it also ap-
pears as a late event in SBA development (29). 
Other abnormalities have been detected in the ex-
pression of cell cycle-related proteins. As in CRC ade-
noma-carcinoma sequence, Arber et al. showed that ove-
rexpression of cyclin D1 and p27, as well as down-re-
gulation of p16 and p21, appear early in the develop-
ment of SBA (30). Smad-4 (Mothers against decapen-
taplegic homolog 4) protein, encoded by Deleted Pan-
creatic Carcinoma (DPC4) gene, is considered as a me-
diator of growth suppression via trasforming growth fac-
tor β (TGF-β) signaling. Homozygous deletion or mu-
tation of DPC4 has been reported in about half of pan-
creatic ductal adenocarcinomas and in 3-50% of colo-
rectal tumors (31, 32). Bläker et al. investigated dele-
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Fig. 1 - CEA immunohistochemical staining (10X). Fig. 2 - EGFR immunostaining reaction (20X): focal positive response.
tions of DPC4 gene in a series of patients with SBA,
founding missense mutations in 24% of tumors (33).
Defects in one or more MMR (mismatch repair) ge-
nes result in the microsatellite instability (MSI) phenoty-
pe in the HNPCC. Such MMR defects probably also
contribute to SBA tumorigenesis, as suggested by the in-
creased risk of SBA among HNPCC patients. The in-
cidence of MSI observed in sporadic SBA varies in the
literature from 11-18%, which is similar to that found
in non-hereditary CRC (34). More than 80% of MSI
tumors found in the colon carry MutL homologue 1
(MLH1) inactivation (35). Planck et al. have reported
that only 50% of MSI tumors in the small bowel exhi-
bit a MLH1 defect (34). Brücher et al. have demonstra-
ted that hypermethylation of human MLH1, HPP1
(Human proto-homogene 1), p14ARF, p16INK4A and APC
(Adenomatous Polyposis Coli), is a frequent finding in
SBA. They suggest that hypermethylation plays a signi-
ficant role in the molecular carcinogenesis of SBA, com-
parable with other gastrointestinal tumors (16).
Despite several similarities, some genetic events ap-
pear to be distincted between SBA and CRC. For in-
stance, mutations and deletions of APC gene, as well as
alteration in the so-called deleted colorectal cancer
(DCC) gene are considered frequent early events in
CRC, but occur rarely in SBA. However, reduced ex-
pression of β-catenin, without associated APC abnor-
mality, was observed in SBA patients studied by Whee-
ler et al., suggesting β-catenin itself is mutated and able
to induce SBA (36).
Lee et al. studied the expression of mucins (MUC)
and cytokeratins (CK) in primary carcinomas of the di-
gestive system. They found that CK20 was highly ex-
pressed in the colon (77%), appendix (100%), and anus
cancers (80%). The rate of CK20 positivity in small
bowel was 48%. The expression patterns of MUC1,
MUC2, and CK20 were significantly different between
the duodenum cancers and those of the remaining small
intestine. The duodenum cancers showed MUC1+,
MUC2-, and CK20-. On the other hand, jejunal and
ileal cancers showed an opposite expression pattern, that
is MUC1-, MUC2+, and CK20+. MUC1 and CK20
provide a significant distinction between right colon can-
cers (negativity) and left colon cancers (53% of positi-
vity) (37).
Epidermal growth factor receptor belongs to the
ErbB family. This family is comprised by transmembra-
ne proteins that form part of the tyrosine kinase recep-
tor proteins which are activated by different kinds of li-
gands. There are four different receptors in the ErbB fa-
mily named ErbB1 (EGFR; HER or c-erbB, the first to
be described), ErbB2 (HER2/neu), ErbB3 (HER3) and
ErbB4 (HER4) (38). The oncogene c-neu is altered in
approximately 50% of sporadic CRC. Zhu et al. repor-
ted that 60% of tumors in their patients series were po-
sitive for mutation, and the oncogene expression was
seen to increase directly with tumor grade (39). Dysre-
gulation of the EGFR signaling pathway because of EG-
FR overexpression, genetic aberrations, or other causes
leads to malignant transformation. Recent studies have
shown that EGFR expression is present in approxima-
tely 60% to 80% of colorectal carcinomas, and the re-
ceptor has emerged as a rational target for anticancer the-
rapy in these tumors (40). EGFR positivity within the
small intestine appeared to be almost entirely restricted
to the proliferative (crypt) region (41). The role of EG-
FR in the tumorigenesis of SBA has not been defined
as yet. We retain that it could be another possible area
to investigate for the new of treatments of SBA, simi-
larly to CRC.
In a recent study, Zhang et al. have immunohisto-
chemically compared SBA with CRC for the expression
of MUC1, MUC2, and MUC5AC, small-intestinal mu-
cin antigen (SIMA), villin, and Cdx2. They found that
MUC1 is similarly overexpressed in SBA and CRC.
However, SBA exhibit more frequent loss of expression
of MUC2 and less frequent overexpression of MUC5AC
compared with CRC. The Authors observed that poorly
differentiated SBA overexpress MUC1 more frequently
than better differentiated SBA, stressing that up-regu-
lation of MUC1 expression in CRC is a marker of poor
prognosis. Furthermore they reported that SIMA and
villin are also expressed in SBA. However, only half of
the SBA included in this study showed SIMA immu-
noreactivity (and 80% of them displayed a focal staining
pattern), while two third of SBA stained positively for
villin (with 50% of focal response). These findings are
in contrast with CRC in which diffuse SIMA and vil-
lin expression is demonstrated in the majority of the ca-
ses (42). 
Cdx2 gene, which encodes a homeodomain tran-
scription factor required for the development and main-
tenance of the intestinal epithelium, is a tumor suppres-
sor in the colon ad rectum (43). A cardinal property de-
fining tumor suppressors is their inactivation in cancer
cells compared with normal cells. Cdx2 is not a classic
tumor suppressor. In fact the study of Witek et al. shows
that Cdx2 is overexpressed in most sporadic human co-
lorectal tumors (>80% of CRC) compared with matched
normal mucosa. Less than 20% of sporadic CRC exhi-
bit reduced or absent Cdx2 expression. The precise me-
chanism underlying the overexpression of Cdx2 remains
still undefined. It could represent a compensatory me-
chanism to reestablishing the equilibrium in prolifera-
tion and differentiation of the cell. Although Witek sug-
gests the possibility that Cdx2 could serve as an onco-
gene in the gastrointestinal tract, and its overexpression
reflects the role in mediating euplastic transformation
(43). Cdx2 expression has been examined in a limited
number of SBA (44). In the study of Zhang, Cdx2 im-
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munoreactivity is detected in only 60% of SBA, in con-
trast with 98% of CRC (42). Witek suggests the parti-
cular versatility of Cdx2 in regulating both proneopla-
stic and antineoplastic pathways and highlights the im-
portance of further studies to define its complex role
(43). We retain that it could be helpful also in the bet-
ter comprehension of the tumorigenesis of SBA.
From the analysed literature about SBA, we could
make many speculations about pathogenesis of obser-
ved ileal adenocarcinoma. We suppose that some spo-
radic somatic mutations have occurred in our patient
only at ileal level, without involvement of colonic mu-
cosa. In particular, the lack of expression of Cdx2 in our
case can suggest a role of this tumor suppressor gene in
carcinogenesis, inducing to suppose the existence of dif-
ferent mutations and different activation pathways for
the same gene. Finally we still remark the importance
of better understanding of the pathogenesis and tumo-
rigenesis of SBA in order to develop new therapeutic
strategies for the future.
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